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Abstract
Introduction: There are few reported cases of neutrophilic pleural effusions associated with
valproic acid therapy. Most of them are of eosinophilic exudates with or without blood
eosinophilia.
Case presentation: This case study describes a 70-year-old man with recurrent episodes of
eosinophilic transudative pleural effusions associated with sodium valproate treatment. The
recurrence of effusion after re-administration of the drug is strongly suggestive of an association
between them. To the best of our knowledge, this is the first reported case with a pleural effusion
with these characteristics caused by sodium valproate.
Conclusion: This is the first report in the literature, with a full understanding of the etiology but
with an unknown drug mechanism. This case report is of interest to different medical specialists
(such as pulmonologists, neurologists, cardiologists) and pharmacologists.
Introduction
This case study describes a 70-year-old man with recurrent
episodes of neutrophilic transudative pleural effusions
associated with sodium valproate re-administration. To
the best of our knowledge, there are only five reported
cases of pleural effusion associated with valproic acid
therapy, but this is the first reported case of a pleural effu-
sion with these characteristics.
Case presentation
A 70-year-old male smoker (45 py), ex-farmer, was admit-
ted to our department because of fever (38.8°C), dry
cough and dyspnea. His symptoms commenced 5 days
before his admission. He reported the same symptoms 8
months earlier when he had been admitted to another
hospital. A chest radiograph had shown a large right-sided
pleural effusion (Figure 1) and diagnostic thoracentesis
had revealed a neutrophilic transudate. The fluid had
been drained (700 ml of fluid) and the patient had left the
hospital asymptomatic with a normal chest X-ray rejecting
any further investigation.
His past history revealed atrial fibrillation (treated with
digoxin), and post-traumatic epilepsy, after a road acci-
dent 1 year previously, treated since then with sodium val-
proate 500 mg/day.
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On admission, the patient was febrile, tachypneic and
looked moderately ill. Physical examination of the chest
showed dullness on percussion at the middle and lower
part of the right hemithorax as well as decreased breath
sounds. The rest of the clinical examination was unre-
markable. Standard laboratory studies demonstrated mild
anemia (Ht = 32.2% and Hb = 9.7 mg/dl) and slightly
increased erythrocyte sedimentation rate (ESR = 47 mm/
h) and C-reactive protein (CRP = 2.8 mg/l). No leukocy-
tosis or eosinophilia was observed. A postero-anterior
chest X-ray showed a right-sided pleural effusion. Diag-
nostic thoracentesis revealed a neutrophilic transudative
pleural effusion [total cell count = 100/μl, mainly neu-
trophils (65%)], glucose = 95 mg/dl, LDH = 30 IU/L, total
proteins = 3 g/dl, albumin = 1 g/dl). A therapeutic thora-
centesis (drainage of 1200 ml of fluid) resulted in dyspnea
relief. Further laboratory investigation, including serum
complement analysis, rheumatoid factor, antinuclear
antibodies, thyroid hormones, antineutrophilic cytoplas-
matic antibodies, immunoglobulin levels, serologic tests
for hepatitis A, B and C, as well as for common viruses and
atypical infectious agents, disclosed no apparent patholo-
gies. HIV tests were also negative. Serum protein electro-
phoresis was also normal.
The echocardiography examination was normal. Con-
trast-enhanced computed tomography (CT) of the chest
performed 1 day later revealed pleural fluid accumulation
in both pleural cavities (Figure 2), while spiral CT pulmo-
nary arterial angiography obtained simultaneously was
negative for pulmonary embolism.
After exclusion of all possible reasons for the observed
transudative pleural effusion, sodium valproate was dis-
continued and replaced with gabapentin (300 mg/day).
During this period, the patient did not receive any other
medication. Patient follow-up at 15 days, 1 and 2 months
after his admission showed no relapse.
Seven months later, the patient had an epileptic episode
and he changed his therapy on his own, from gabapentin
to sodium valproate again. A month later, he was readmit-
ted to our hospital because of dyspnea, fever, mild anemia
with elevated CRP on laboratory tests and a right-sided
pleural effusion on chest X-ray. Examination of the pleu-
ral fluid showed a transudative effusion with a small
number of cells (90/μl), mainly neutrophils (87%).
Sodium valproate was discontinued and gabapentin was
re-administered in higher doses (400 mg, twice a day), in
order to avoid seizure relapse. This treatment was gradu-
ally followed by alleviation of the symptoms, elevation of
hematocrit and normalization of CRP. No pleural fluid
recurrence was observed after a sequential follow-up, up
to 6 months later.
Discussion
To the best of our knowledge, this is the first reported
patient with a transudative pleural effusion due to valp-
roic acid therapy. Adverse reactions to drugs produce only
a small percentage of all pleural effusions; however, it is
important to consider the possibility of drug-induced
pleural disease after the exclusion of all other possible
causes.
Chest retro-anterior radiograph showing a large right-sided  pleural effusion without lung parenchymal disorders Figure 1
Chest retro-anterior radiograph showing a large 
right-sided pleural effusion without lung parenchy-
mal disorders.
Contrast-enhanced computed tomography of the chest  revealing pleural fluid accumulation in both pleural cavities Figure 2
Contrast-enhanced computed tomography of the 
chest revealing pleural fluid accumulation in both 
pleural cavities. The occurrence of lung parenchyma is 
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Valproic acid and its derivative – sodium valproate – are
frequently used for the treatment of bipolar disorder, and
are also used as an adjunct medication in patients with
post-traumatic epilepsy and psychotic disorders such a
schizophrenia [1]. Common side effects include nausea,
weight gain, somnolence, and tremor. Hepatotoxicity has
been reported in some cases. Serum eosinophilia is a pos-
sible but usually insignificant side effect.
A review of the literature revealed only five reported cases
of pleural effusions associated with valproic acid therapy.
Most of them were eosinophilic exudates with or without
blood eosinophilia. The first case [2] referred to a patient
with an exudative eosinophilic pleural effusion, which
may have been caused by valproic acid or the concomi-
tantly administered antipsychotic medication (chlorpro-
mazine and fluphenazine) or by a potentiation effect.
Since valproic acid and antipsychotics were used in com-
bination, medication side effects [3] or interaction [4]
should be considered as causative mechanisms. Two other
case reports [5,6] described exudative eosinophilic pleural
effusions with peripheral blood eosinophilia. No cause of
the pleural effusion was found, but on cessation of valp-
roic acid therapy, the pleural effusion and eosinophilia
resolved in both patients. The other reported case [7]
referred to a patient with a 'flu-like syndrome' and both
pleural and pericardial (non-eosinophilic) effusion after
long-term therapy with valproate. The last case was of
lymphocytic pleural effusion [8].
Our patient presented with fever, fatigue, dyspnea and
neutrophilic transudative pleural effusions in all three of
his hospitalizations. No peripheral eosinophilia was
observed. Valproic acid was suggested as the cause of the
pleural effusion after exclusion of all other possible
causes. Although the clinical picture of the patient, his
laboratory blood tests as well as the presence of neu-
trophils in the pleural fluid suggested an inflammatory
reaction, the rest of the characteristics of the pleural effu-
sion were compatible with a transudate. A transudative
effusion usually does not imply an inflammation, but
instead disequilibrium of the hydrostatic and osmotic
driving pressures between the pleural space and the capil-
lary bed of the pleura. This was virtually excluded in our
patient, since cardiac and renal functions as well as blood
protein levels were all normal. A possible side effect of val-
proic acid on heart function was excluded as the echocar-
diography test was normal. Furthermore, it has been
reported that intravenous injection of valproate at high
concentrations, large doses and fast infusion rates pro-
duce no evidence of cardiotoxicity [9].
The explanation of the presence of a transudative pleural
effusion in our patient is obscure. However, the most per-
suasive evidence that the whole clinical situation was due
to the suspected drug was the recurrence of the pleural
effusion whenever the regimen was administered and the
disappearance of the effusion whenever the drug was dis-
continued. Indeed, after his final admission, the patient's
clinical symptoms subsided with the discontinuation of
valproic acid, while no pleural fluid recurrence was
observed on follow-up thereafter.
The potential causative mechanism remains elusive, but,
still, the recurrence of effusion after re-administration of
the drug is strongly suggestive of an association. However,
it has been suggested that viral infections (rhinopharyngi-
tis) may induce these adverse events (fever, pleuritis) and
additionally may cause clinically significant episodes of
thrombocytopenia in these patients [10]. On the other
hand, bone marrow suppression and pulmonary hemor-
rhage have only been reported [11] in valproate over-
doses.
Conclusion
This is the first reported case with a transudative pleural
effusion due to valproic acid therapy, and this should be
considered after all other possible causative factors have
been excluded.
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